This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Click here for ReFacto AF® (moroctocog alfa) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

​​​​​​​Reliable efficacy when you and your patients need it most1,2


Prophylactic treatment in PTPs

Reduction in annual bleed rate (ABR) vs on-demand in previously treated patients (PTPs). ReFacto AF prophylaxis is more effective at preventing bleeds than on-demand treatment, with an 85% reduction of bleeds per year (median ABR: 3.4; n=154) 
achieved with prophylactic treatment3

On-demand treatment

On-demand treatment in PTPs

of 10,882 bleeding episodes were treated effectively with only 1 infusion (n=113)1,2

On-demand treatment in previously untreated patients (PUPs)

of 2,715 bleeding episodes were treated effectively with only 1 infusion (n=101)1,2


of infusions administered were rated as excellent or good by the surgeon and treating physician (38 patients; 48 surgical procedures; 496 infusions during or after surgery)1,*

ReFacto AF is manufactured using the same cell line as ReFacto4 and is bioequivalent to ReFacto and pharmacokinetically equivalent to a full-length recombinant factor VIII (FLrFVIII) comparator5, so it is expected to behave in the same way.

​​​​​​​*Excellent rating: achievement of comparable haemostasis to that expected after similar surgery in a non-haemophilic patient. Good rating: prolonged time to haemostasis with somewhat increased bleeding compared with that expected after similar surgery in a non-haemophilic patient.1

Explore more

Find out about the safety profile of ReFacto AF. 

Click here

Find out about ReFacto AF dosing for on-demand treatment and prophylaxis

Click here

ABR = annualised bleeding rate;
BU = Bethesda units;
PTP = previously treated patient;
​​​​​​​PUP = previously untreated patient.
  1. Lusher JM et al. The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia. Haemophilia 2003;9:38–49.
  2. Lusher JM and Roth DA. The safety and efficacy of B-domain deleted recombinant factor VIII concentrates in patients with severe haemophilia A: an update. Haemophilia 2005;11:292–293.
  3. Parra Lopez R et al. Prospective surveillance study of haemophilia A patients switching from moroctocog alfa or other factor VIII products to moroctocog alfa albumin-free cell culture (AF-CC) in usual care settings. Thromb Haemost. 2015;114(4):676–684.
  4. Kelley B et al. An improved manufacturing process for Xyntha/ReFacto AF. Haemophilia 2010;16(5):717–725.
  5. ReFacto AF (moroctocog alfa) Summary of Product Characteristics:
PP-REF-GBR-0196. March 2021

Contact Pfizer

Speak to a member of the Pfizer Haemophilia team.

Click here

Find out about the ReFacto AF Laboratory Standard

How to order

Educational materials for children with haemophilia

Find out more

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020